Description
During this workshop, novel approaches to treating CF lung disease will be presented and discussed. This session will also focus on outcome measures that reflect response to therapy in CF.
- Identify novel mechanisms of action in which CFTR can be activated.
- Define the role of other transport processes in clearing the CF airway surface liquid.
- Identify novel assays and biomarkers to measure improvement in CF lung disease and to assess long-term effects of therapeutic agents.
Workshop Chair(s):
Workshop Speaker(s):
- Felix
Ratjen,
M.D., Ph.D.,
Division Head of Respiratory Medicine
- Patrick
Flume,
M.D.,
Professor of Medicine and Pediatrics
- Corina
Balut,
Ph.D.,
AbbVie Inc
- Timothy
J. Stuhlmiller,
Ph.D.,
Spyryx Biosciences
- Alan
Brody,
M.N.,
Cincinnati Children's Hospital
